3-[(3-Methoxyphenyl)methyl]imidazole-4-carbaldehyde | 238764-94-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-[(3-Methoxyphenyl)methyl]imidazole-4-carbaldehyde
• CAS: 238764-94-8
• 化学式: C₁₂H₁₂N₂O₂
• 分子量: 216.239
• InChiKey: XHDHHIJMWOXYQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氨基-[1,1'-联苯]-2-甲酸甲酯 、 3-[(3-Methoxyphenyl)methyl]imidazole-4-carbaldehyde 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 Methyl 4-[[3-[(3-methoxyphenyl)methyl]imidazol-4-yl]methylamino]-2-phenylbenzoate
  参考文献：
  名称：

  Structurally Simple Inhibitors of Lanosterol 14α-Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease

  摘要：

  We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14 alpha-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T cruzi amastigotes in vitro with values of EC50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.

  DOI：

  10.1021/jm900030h
• 作为产物：
  描述：

  3-甲氧基溴苄 、 1-三苯甲基咪唑-4-甲醛 以 乙腈 为溶剂， 生成 3-[(3-Methoxyphenyl)methyl]imidazole-4-carbaldehyde
  参考文献：
  名称：

  Structurally Simple Inhibitors of Lanosterol 14α-Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease

  摘要：

  We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14 alpha-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T cruzi amastigotes in vitro with values of EC50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.

  DOI：

  10.1021/jm900030h

文献信息

• [EN] CONDENSED HETEROCYCLIC SYSTEM DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES DE SYSTEMES HETEROCYCLIQUES CONDENSES, LEUR PREPARATION, LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
  申请人：AVENTIS PHARMA S.A.

  公开号：WO1999041248A1

  公开（公告）日：1999-08-19

  (EN) The invention concerns novel products of general formula (I), their preparation, pharmaceutical compositions containing them and the use thereof for preparing medicines. In general formula (I) R1 represents a -CO-CH(NH2)-CH2SH, or -CH2-CH(NH2)-CH2SH, or -CHRi1Ri2 radical; R2 represents a hydrogen atom, an alkyl, aralkyl, aryl, alkylcarbonyl, aralkylcarbonyl, heterocycloalkyl radical; R3 represents a hydrogen atom or a halogen atom or an alkyl, aryl, aralkyl radical; R4 represents a -CHRi3Ri4 radical; R5 represents a hydrogen atom, or a -C(O)-Ri5 radical; R6 represents a hydrogen atom or an alkyl, aryl, aralkyl radical; R7, R8 represent a hydrogen atom or an alkyl, aryl, aralkyl radical; X represents a hydrogen atom or a -S(O)1 radical.(FR) Nouveaux produits de formule générale (I), leur préparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la préparation de médicaments. Dans la formule générale (I), R1 représente un radical -CO-CH(NH2)-CH2SH, ou -CH2-CH(NH2)-CH2SH, ou -CHRi1Ri2; R2 représente un atome d'hydrogène, un radical alkyle, aralkyle, aryle, alkylcarbonyle, aralkylcarbonyle, arylcarbonyle, hétérocyclalkyle; R3 représente un atome d'hydrogène ou un atome d'halogène ou un radical alkyle, aryle, aralkyle; R4 représente un radical -CHRi3Ri4; R5 représente un atome d'hydrogène, ou un radical -C(O)-Ri5; R6 représente un atome d'hydrogène ou un radical alkyle, aryle, aralkyle; R7, R8 représentent un atome d'hydrogène ou un radical alkyle, aryle, aralkyle; X représente un atome d'oxygène ou un radical -S(O)1.

  本发明涉及一般式（I）的新型产品，其制备，包含它们的药物组合物以及用于制备药物的它们的使用。在一般式（I）中，R1代表-CO-CH（NH2）-CH2SH或-CH2-CH（NH2）-CH2SH或-CHRi1Ri2基团；R2代表氢原子，烷基，芳基烷基，芳基，烷基羰基，芳基烷基羰基，杂环烷基基团；R3代表氢原子或卤素原子或烷基，芳基，芳基烷基基团；R4代表-CHRi3Ri4基团；R5代表氢原子或-C（O）-Ri5基团；R6代表氢原子或烷基，芳基，芳基烷基基团；R7，R8代表氢原子或烷基，芳基，芳基烷基基团；X代表氢原子或-S（O）1基团中的氧原子。
• DERIVES DE SYSTEMES HETEROCYCLIQUES CONDENSES, LEUR PREPARATION, LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
  申请人：Aventis Pharma S.A.

  公开号：EP1054882A1

  公开（公告）日：2000-11-29
• Structurally Simple Inhibitors of Lanosterol 14α-Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease
  作者：Praveen Kumar Suryadevara、Srinivas Olepu、Jeffrey W. Lockman、Junko Ohkanda、Mandana Karimi、Christophe L. M. J. Verlinde、James M. Kraus、Jan Schoepe、Wesley C. Van Voorhis、Andrew D. Hamilton、Frederick S. Buckner、Michael H. Gelb

  DOI：10.1021/jm900030h

  日期：2009.6.25

  We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14 alpha-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T cruzi amastigotes in vitro with values of EC50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.